Breast cancer is the most common cancer in women worldwide, constituting？25% of all cancer diagnoses. Even though it is only affecting 4%？-？6% of women under？the age of 40, it remains？the most common malignancy among younger？patients. Advancement in the treatment and earlier detection gives？excellent 5？years？of？survival. However,？the？standard treatment？that？comprises surgical-chemo？radiation therapy or hormonal treatment often results
References
[1]
Sung, H., Ferlay, J., Rebecca, L., et al. (2021) Global Cancer Statistics 2020: Global Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
[2]
AIHW Australian Cancer Database 2018. https://www.semanticscholar.org
[3]
Eric, I., Eric, P.A. and Kristek, J. (2018) Breast Cancer in Young Women: Pathologic and Immunohistochemical Features. Acta Clinica Croatica, 57, 497-502.
[4]
Copson, E.R., Maishman, T.C., Tapper, W.J., et al. (2018) Germline BRCA Mutation and Outcome in Young-Onset Breast Cancer (POSH): A Prospective Cohort Study. The Lancet Oncology, 19, 169-180. https://doi.org/10.1016/S1470-2045(17)30891-4
[5]
Partridge, A.H., Gelber, S., Peppercorn, J., et al. (2016) Web-Base Survey of Fertility Issue in Young Women with Breast Cancer. Journal of Clinical Oncology, 22, 4174-4183. https://doi.org/10.1200/JCO.2004.01.159
[6]
Logan, S. and Anazodo, A. (2019) The Psychological Importance of Fertility Preservation Counselling and Support for Cancer Patients. Acta Obstetricia Gynecologica Scandinavica, 98, 583-597. https://doi.org/10.1111/aogs.13562
[7]
Gerst, B., Sullivan, E., Ives, A. and Sauders, C. (2018) Pregnancy Outcomes after Breast Cancer Diagnosis: A Systematic Review and Meta-Analyses. Clinical Breast Cancer, 18, e79-e88. https://doi.org/10.1016/j.clbc.2017.06.016
[8]
Kasum, M., et al. (2014) Fertility after Breast Cancer Treatment. The European Journal of Obstetrics & Gynecology and Reproductive Biology, 173, 13-18.
https://doi.org/10.1016/j.ejogrb.2013.11.009
[9]
Lambertini, M., Auserini, P., et al. (2013) Fertility Counselling of Young Breast Cancer Patients. Journal of Thoracic Disease, 5, s68-s80.
[10]
Shnorhavorian, M., Harlan, L.C. and Smith, A.W. (2015) Fertility Preservation Knowledge, Counselling and Action among Adolescence and Young Adult Patient with Cancer: A Population Based Study. Cancer, 121, 3499-3506.
https://doi.org/10.1002/cncr.29328
[11]
Cardoso, F., Kyriakides, S., Ohno, S., et al. (2019) Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 30, 1194-1220. https://doi.org/10.1093/annonc/mdz173
[12]
Partridge, A.H., Ruddy, K.J., Gelber, S., et al. (2010) Ovarian Reserved in Women Who Remain Premenopause after Chemotherapy for Early Stage Breast Cancer. Fertility and Sterility, 94, 638-644. https://doi.org/10.1016/j.fertnstert.2009.03.045
[13]
Parisi, F., Razeti, M.G., Lambertini, M., et al. (2020) Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patient with Early Breast Cancer. Clinical Medicine. Oncology, 14, 1-10. https://doi.org/10.1177/1179554920931816
[14]
Peto, R., Davis, C., et al. (2012) Comparison between Polychemotherapy Regimens for Early Breast Cancer: Meta Analysis of Long-Term Outcome among 100000 Women 123 Randomized Trials. The Lancet, 379, 432-444.
https://doi.org/10.1016/S0140-6736(11)61625-5
[15]
Denduluri, N., Chavez Mac Gregor, M., Telli, M.L., et al. (2018) Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer. ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 36, 2433-2443. https://doi.org/10.1200/JCO.2018.78.8604
[16]
Caparica, R., Bruzzone, M., Poggio, F., Ceppi, M., et al. (2019) Anthracycline and Taxane-Based Chemotherapy versus Docetaxel and Cyclophosphamide in the Adjuvant Treatment of HER2 Negative Breast Cancer Patient: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Breast Cancer Research and Treatment, 174, 27-37. https://doi.org/10.1007/s10549-018-5055-9
[17]
Tolaney, S.M., Guo, H., Pernas, S., et al. (2019) Seven Years Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node Negative HER2 Positive Breast Cancer. Journal of Clinical Oncology, 37, 1868-1875.
https://doi.org/10.1200/JCO.19.00066
[18]
Cortazar, P., Zhang, L., Untch, M., et al. (2014) Pathological Complete Response and Long Term Clinical Benefit in Breast Cancer. The Lancet, 384, 164-172.
https://doi.org/10.1016/S0140-6736(13)62422-8
[19]
Masuda, N., Lee, S.J., Ohtani, S., et al. (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England Journal of Medicine, 376, 2147-2159. https://doi.org/10.1056/NEJMoa1612645
[20]
Sparano, J.A., Gray, R.J., Makower, D.F., et al. (2018) Adjuvant Chemothepay Guided by a 21-Gene Expression Assay in Breast Cancer. The New England Journal of Medicine, 379, 111-121. https://doi.org/10.1056/NEJMoa1804710
[21]
Overbeek, A., Berg, M.H. and Flora, E. (2017) Chemotherapy-Related Late Adverse Effects on Ovarian Function in Female Survivors of Childhood and Young Adult Cancer: A Systematic Review. Cancer Treatment Reviews, 53, 10-24.
https://doi.org/10.1016/j.ctrv.2016.11.006
[22]
Parulakar, W.R., Day, A.G., Ottaway, J.A., et al. (2005) Incidence and Prognostic Impact of Amenorrhea during Adjuvant Therapy in High Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada. Journal of Clinical Oncology, 23, 6002-6008. https://doi.org/10.1200/JCO.2005.07.096
[23]
Zavos, A. and Valachis, A. (2016) Risk of Chemotherapy Induced Amenorrhea in Patient with Breast Cancer: A Systematic Review and Meta-Analysis. Acta Oncologica, 55, 664-670. https://doi.org/10.3109/0284186X.2016.1155738
[24]
Ruddy, K.J., Hao, G., William, B., et al. (2015) Chemotherapy-Related Amenorrhea after Adjuvant Paclitaxel-Trastuzumab (APT Trial). Breast Cancer Treatment, 151, 589-596. https://doi.org/10.1007/s10549-015-3426-z
[25]
Freour, T., Barriere, P. and Mason, D. (2017) AMH Levels and Evolution in Women of Reproductive Age with Breast Cancer Treated with Chemotherapy. European Journal of Cancer, 74, 1-8. https://doi.org/10.1016/j.ejca.2016.12.008
[26]
Romito, A., Bove, S., Zace, D., Raimondo, I., et al. (2021) Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 11, Article 704. https://doi.org/10.3390/jpm11080704
[27]
Lambertini, M., Olympios, N., Lequesne, J., et al. (2019) Impact of Taxane, Endocrine Therapy and Deleterious Germline BRCA Mutations on Anti-Müllerian Level in Early Breast Cancer Patient Treated with Anthracycline and Cyclophosphamide Base Chemotherapy. Frontiers in Oncology, 9, Article 575.
https://doi.org/10.3389/fonc.2019.00575
[28]
Chiu, J.W., Leung, R., Tang, V., et al. (2019) Changing Pattern of Recurrences in Patients with Early HER2 Positive Breast Cancer Receiving Neoadjuvant Chemotherapy in the Era of Dual Anti-HER2 Therapy. Postgraduate Medical Journal, 95, 155-161. https://doi.org/10.1136/postgradmedj-2018-135739
[29]
Lambertini, M., Campbell, C., et al. (2019) Adjuvant Anti-HER2 Therapy Treatment Related Amenorrhea and Survival in Premenopausal HER2 Positive Early Breast Cancer Patients. JNCI: Journal of the National Cancer Institute, 111, 86-94.
https://doi.org/10.1093/jnci/djy094
[30]
Zagouri, F., Sergentanis, T.N., Chrysikos, D., et al. (2013) Trastuzumab Administration during Pregnancy: A Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment, 137, 349-357. https://doi.org/10.1007/s10549-012-2368-y
[31]
Burstein, H.J., et al. (2018) Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 37, 423-438.
https://doi.org/10.1200/JCO.18.01160
[32]
Goss, P.E., Ingle, J., Martino, S., et al. (2013) Impact of Premenopausal Status at Breast Cancer Diagnosis in Women Entered on the Placebo-Controlled NCIC CTG MA17 Trial of Extended Adjuvant Letrozole. Annals of Oncology, 24, 355-361.
https://doi.org/10.1093/annonc/mds330
[33]
Gnant, M., Mlineritsch, B., Stoeger, H., et al. (2015) Zoledronic Acid Combined with Adjuvant Endocrine Therapy of Tamoxifen versus Anastrozol plus Ovarian Function Suppression in Premenopausal Early Breast Cancer: Final Analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of Oncology, 26, 313-320. https://doi.org/10.1093/annonc/mdu544
[34]
Shandley, L.M., Spencer, J.B., Forthergill, A., et al. (2016) Impact of Tamoxifen Therapy on Fertility in Breast Cancer Survivor. Fertility and Sterility, 10, 20.
[35]
Larena, N.C., Estevez, S.L., Tucker, S.L., et al. (2015) Impact of Fertility Concerns on Tamoxifen Initiation and Persistence. JNCI: Journal of the National Cancer Institute, 107, Article No. 202. https://doi.org/10.1093/jnci/djv202
[36]
Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer (POSITIVE). Clinical Trial.gov Identifier: NCT02308085.
[37]
Lambertini, M., Blondeaux, E., Bruzzone, M., et al. (2021) Pregnancy after Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 39, 3293-3305. https://doi.org/10.1200/JCO.21.00535
[38]
Oktay, K., Harvey, B.E., Partridge, A.H., et al. (2018) Fertility Preservation in Patient with Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 36, 1994-2001. https://doi.org/10.1200/JCO.2018.78.1914
[39]
Rodgers, R.J., Reid, G.D., Juliette, K., et al. (2017) The Safety and Efficacy of Controlled Ovarian Hyperstimulation for Fertility Preservation in Women with Early Breast Cancer: A Systematic Review. Human Reproduction, 32, 1033-1045.
https://doi.org/10.1093/humrep/dex027
[40]
Shapira, M., Raanani, H. and Meirow, D. (2015) IVF for Fertility Preservation in Breast Cancer Patients—Efficacy and Safety Issues. Journal of Assisted Reproduction and Genetics, 32, 1171-1178. https://doi.org/10.1007/s10815-015-0519-x
[41]
Reddy, J., Turan, V., Bedoschi, G., et al. (2014) Triggering Final Oocyte Maturation with Gonadotropin Releasing Hormone Agonist versus Human Chorionic Gonadotropin in Breast Cancer Patients Undergoing Fertility Preservation: An Extended Experience. Journal of Assisted Reproduction and Genetics, 31, 927-932.
https://doi.org/10.1007/s10815-014-0248-6
[42]
Doyle, J.O., Richter, K.S., et al. (2016) Successful Elective and Medically Indicated Oocyte Vitrification and Warming for Autologous in Vitro Fertilization, with Predicted Birth Probabilities for Fertility Preservation According to Number of Cryopreserved Oocytes and Age at Retrieval. Fertility and Sterility, 105, 459-466.E2.
https://doi.org/10.1016/j.fertnstert.2015.10.026
[43]
Danis, R.B., Nigel, P., et al. (2017) Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women during Fertility Preservation Prior to Gonadotoxic Cancer Therapy. Current Pharmaceutical Biotechnology, 18, 609-613.
https://doi.org/10.2174/1389201018666170808122531
[44]
Pacheco, F. and Oktay, K. (2017) Current Success and Efficiency of Autologous Ovarian Transplantation: A Meta Analysis. Reproductive Sciences, 24, 1111-1120.
https://doi.org/10.1177/1933719117702251
[45]
Shapira, M., Dolmans, M., Silber, S. and Meirow, D. (2020) Evaluation of Ovarian Tissue Transplantation: Results from Three Clinical Centres. Fertility and Sterility, 114, 388-397. https://doi.org/10.1016/j.fertnstert.2020.03.037
